Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
News Focus
SLAM DRILLS MORE COPPER MINERALIZATION AT GOODWIN (click to learn more)
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Theralase Technologies Inc. V.TLT

Alternate Symbol(s):  V.TLT.WT | TLTFF

Healthcare Medical Devices
Theralase Technologies Inc. is a Canada-based clinical-stage pharmaceutical company. The Company is engaged in the research and development of light activated compounds and their associated drug formulations. The Company operates through two divisions: Anti-Cancer Therapy (ACT) and Cool Laser Therapy (CLT). The Anti-Cancer Therapy division develops patented, and patent pending drugs, called Photo Dynamic Compounds (PDCs) and activates them with patent pending laser technology to destroy specifically targeted cancers, bacteria and viruses. The CLT division is responsible for the Company’s medical laser business. The Cool Laser Therapy division designs, develops, manufactures and markets super-pulsed laser technology indicated for the healing of chronic knee pain. The technology has been used off-label for healing numerous nerve, muscle and joint conditions. The Company develops products both internally and using the assistance of specialist external resources.


TSXV:TLT - Post by User

Theralase Technologies Inc. > Today's TLD1433 Shout Out
<< Previous
 Bullboard Posts
Next >>
User Avatar Image
(2941)
•••
Post by Eoganachton Feb 16, 2024 3:13pm
442 Views
Post# 35884864

Today's TLD1433 Shout Out

Today's TLD1433 Shout OutUridine-Modified Ruthenium(II) Complex as Lysosomal LIMP-2 Targeting Photodynamic Therapy Photosensitizer for the Treatment of Triple-Negative Breast Cancer

Qiong Wu, Chanling Yuan, Jiacheng Wang, Guohu Li, Chunguang Zhu, Li Li, Zongtao Wang, Qingshuang Lv, and Wenjie Mei*

Guangdong Pharmaceutical University, Guangzhou, China

Publication Date:February 16, 2024
 


"...Ru(II) polypyridyl complexes possess the advantages of significant Stoke’s shift, strong spin coupling, efficient electron transfer, and rapid energy transfer. (19) After light excitation, Ru(II) complexes boost the effectiveness of intersystem crossing (ISC), allowing molecules to reach the excited triplet state that favors ROS production through electron or energy transfer using oxygen or water molecules as grist for generating toxins that eventuate in the death of tumor cells under hypoxic conditions. (20,21) In 2017, the first Ru-based photosensitizer, TLD1433, entered phase I clinical trials with effective PDT for non-muscle-invasive bladder cancer. (22) Additional studies have shown that Ru(II) polypyridyl complexes are able to function as lysosome-enriched photodynamic photosensitizers that inhibit tumor cell growth. (23−26) Peng et al. reported the synthesis of a red light-stimulated lysosome-targeted Ru(II) complex (Ru–I, [Ru(terpy)(Cl-7-IVQ)I]+), which exhibited significant therapeutic efficacy on breast cancer cells using radiation at 660 nm, both in vitro and in vivo. (27) Chao et al. designed and synthesized a Ru(II) polypyridyl complex within cell targeting lysosomes that demonstrated good water solubility. (28,29) This Ru(II) polypyridyl complex has good photostability and significant two-photon excitation efficiency, with high tumor kill rates. In addition, Mao et al. achieved targeted recognition of lysosomes by introducing nanocarbon-loaded polypyridine Ru(II) complexes. These effectively promote tumor cell death under light excitation. (30) Collectively, these studies suggest that lysosome-targeting Ru(II) complexes will have promising applications as photosensitizers for clinical PDT treatments."
<< Previous
 Bullboard Posts
Next >>
Dealroom for high-potential pre-IPO opportunities